In 2023, pharmaceutical patent owners filed nearly 250 infringement complaints against generic drug manufacturers. More than 90% of those cases were filed in the Districts of Delaware or New Jersey.

This year's filings reflect a consensus about venue in pharmaceutical patent infringement cases that has emerged since the U.S. Supreme Court reinterpreted the patent venue statute in 2017.

Originally published by Law360 - December 1, 2023.